Skip to main content
Erschienen in: Medical Oncology 12/2014

01.12.2014 | Original Paper

Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population

verfasst von: Lei Chen, Qiming Yu, Bixia Liu, Liming Zhu

Erschienen in: Medical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to determine the association of the Forkhead box P3 (FoxP3) rs3761548 polymorphism with the risk of colorectal cancer (CRC). Polymorphism genotyping was detected with polymerase chain reaction-polyacrylamide gel electrophoresis (PCR-PAGE), and data revealed that the AA, AC, and the combined A variant genotype (AA+AC) conferred a significantly greater risk of CRC [OR (95 % CI) = 2.806 (1.726–4.563), 1.54 (1.121–2.11), and 1.797 (1.344–2.404), respectively]. Moreover, the A allele of rs3761548 was observed to be associated with higher susceptibility of CRC [OR (95 % CI) = 1.792 (1.424–2.254)]. Unfortunately, no significant association was observed between the two subgroups after stratification by clinical characteristics including age; gender; tumor size, growth pattern, or differentiation; lymph node metastasis; and TNM pathological stage. Thus, we concluded that the FoxP3 gene polymorphism contributes to CRC susceptibility in a Chinese population.
Literatur
1.
Zurück zum Zitat Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. Br J Cancer. 2008;99(1):S30–2.PubMedCentralPubMedCrossRef Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. Br J Cancer. 2008;99(1):S30–2.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.PubMedCrossRef Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–6.PubMedCrossRef
3.
Zurück zum Zitat Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRef Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–52.PubMedCrossRef
4.
5.
Zurück zum Zitat Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PLoS ONE. 2013;8:e53630.PubMedCentralPubMedCrossRef Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PLoS ONE. 2013;8:e53630.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRef Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27:186–92.PubMedCrossRef
7.
Zurück zum Zitat Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE. 2006;1:e129.PubMedCentralPubMedCrossRef Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al. CD4+ CD25+ FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE. 2006;1:e129.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 2002;62:5267–72.PubMed Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res. 2002;62:5267–72.PubMed
9.
Zurück zum Zitat Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig. 2009;119:3311–21.PubMedCentralPubMed Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Investig. 2009;119:3311–21.PubMedCentralPubMed
11.
Zurück zum Zitat Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.PubMedCrossRef
12.
Zurück zum Zitat Zhang L, Zhang Y, Desrosiers M, Wang C, Zhao Y, Han D. Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Hum Immunol. 2009;70(11):930–4.PubMedCrossRef Zhang L, Zhang Y, Desrosiers M, Wang C, Zhao Y, Han D. Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Hum Immunol. 2009;70(11):930–4.PubMedCrossRef
13.
Zurück zum Zitat Bossowski A, Borysewicz-Sańczyk H, Wawrusiewicz-Kurylonek N, Zasim A, Szalecki M, Wikiera B, et al. Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases. Autoimmunity. 2014;47(6):395–400.PubMedCrossRef Bossowski A, Borysewicz-Sańczyk H, Wawrusiewicz-Kurylonek N, Zasim A, Szalecki M, Wikiera B, et al. Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases. Autoimmunity. 2014;47(6):395–400.PubMedCrossRef
14.
Zurück zum Zitat Gao L, Li K, Li F, Li H, Liu L, Wang L, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci. 2010;57(1):51–6.PubMedCrossRef Gao L, Li K, Li F, Li H, Liu L, Wang L, et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. J Dermatol Sci. 2010;57(1):51–6.PubMedCrossRef
15.
Zurück zum Zitat Jahan P, Ramachander VR, Maruthi G, Nalini S, Latha KP, Murthy TS. Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 2014;35(4):3785–91.PubMedCrossRef Jahan P, Ramachander VR, Maruthi G, Nalini S, Latha KP, Murthy TS. Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol. 2014;35(4):3785–91.PubMedCrossRef
16.
Zurück zum Zitat Lopes LF, Guembarovski RL, Guembarovski AL, Kishima MO, Campos CZ, Oda JM, et al. FOXP3 transcription Factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014;2014:341654.PubMed Lopes LF, Guembarovski RL, Guembarovski AL, Kishima MO, Campos CZ, Oda JM, et al. FOXP3 transcription Factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014;2014:341654.PubMed
17.
Zurück zum Zitat Chen Y, Zhang H, Liao W, Zhou J, He G, Xie X, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.PubMedCentralPubMedCrossRef Chen Y, Zhang H, Liao W, Zhou J, He G, Xie X, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Littman DR, Rudensky A. Th17 and regulatory T Cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef Littman DR, Rudensky A. Th17 and regulatory T Cells in mediating and restraining inflammation. Cell. 2010;140:845–58.PubMedCrossRef
20.
Zurück zum Zitat Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K, et al. Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med. 2014;7(7):1781–5.PubMedCentralPubMed Liu Z, Huang Q, Liu G, Dang L, Chu D, Tao K, et al. Presence of FOXP3(+)Treg cells is correlated with colorectal cancer progression. Int J Clin Exp Med. 2014;7(7):1781–5.PubMedCentralPubMed
21.
Zurück zum Zitat Ling A, Edin S, Wikberg ML, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–9.PubMedCentralPubMedCrossRef Ling A, Edin S, Wikberg ML, Öberg Å, Palmqvist R. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues. Br J Cancer. 2014;110(10):2551–9.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Rep. 2011;4(2):203–8.PubMed Aiello M, Vella N, Cannavo C, Scalisi A, Spandidos DA, Toffoli G, et al. Role of genetic polymorphisms and mutations in colorectal cancer therapy. Mol Med Rep. 2011;4(2):203–8.PubMed
23.
Zurück zum Zitat Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36(7):550–6.PubMedCrossRef Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev. 2010;36(7):550–6.PubMedCrossRef
Metadaten
Titel
Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population
verfasst von
Lei Chen
Qiming Yu
Bixia Liu
Liming Zhu
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 12/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0374-0

Weitere Artikel der Ausgabe 12/2014

Medical Oncology 12/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.